MOL
PHARM

Evidence for Biphasic Effects of Protein Kinase C on Serotonin Transporter Function, Endocytosis, and Phosphorylation

MOLECULAR PHARMACOLOGY

Lankupalle D. Jayanthi, Devadoss J. Samuvel, Randy D. Blakely, and Sammanda Ramamoorthy

Department of Physiology and Neuroscience, Medical University of South Carolina, Charleston, South Carolina (L.D.J., D.J.S., S.R.); and Department of Pharmacology and Center for Molecular Neuroscience, Vanderbilt University School of Medicine, Nashville, Tennessee (R.D.B.)

ABSTRACT

The serotonin transporter (SERT) regulates 5-hydroxytryptamine (serotonin) (5-HT) neurotransmission and is a high-affinity target for antidepressants and psychostimulants. In the present study, we investigated the mechanisms that contribute to a previously unidentified biphasic regulation of endogenous SERTs expressed in the platelets. Treatment of rat platelets with β-phorbol 12-myristate 13-acetate (PMA) for 5 min or less resulted in a rapid inhibition of SERT involving changes in intrinsic activity of the transporter (increased K_m and decreased V_{max}). β-PMA treatment for 30 min or more produced a sustained inhibition of SERT with a decrease only in the V_{max}. Whereas inhibition of SERT activity was detected from 1 to 45 min after phorbol ester addition, the decrease in surface SERT required at least 30 min of phorbol ester incubation. Increased endocytosis of SERT accounted for the decrease in surface SERT at the later point. Protein kinase C (PKC)-mediated phosphorylation of SERT occurs on the plasma membrane during the initial phase of rapid transporter inhibition, and later, the phosphorylated SERT enters the intracellular pool. β-PMA-induced phosphorylation of SERT occurs initially on serine residues(s) and then on threonine residue(s). The initial serine phosphorylation corresponded to the first phase of rapid inhibition mediated by changes in intrinsic activity and/or silencing of SERT. The later phosphorylation on threonine residue(s) corresponded to the later phase of sustained inhibition mediated by an enhanced endocytosis of SERT. Together, these data reveal that in platelets, SERT function is regulated by PKC in a biphasic manner involving both trafficking-dependent and independent mechanisms and that these two events occur at distinct phases of transporter phosphorylation.

5-Hydroxytryptamine (serotonin; 5-HT) controls many behavioral and physiological functions (Jacobs and Fornal, 1995). 5-HT uptake via the cocaine- and antidepressant-sensitive serotonin transporter (SERT) is essential for serotonergic neurotransmission termination (Barker and Blakely, 1995). Altered SERT expression and two polymorphic regions in SERT promoter have been implicated in multiple forms of psychopathology, including depression, suicide, anxiety, aggression, schizophrenia, alcoholism, and drug addiction (Murphy et al., 2004). Although clearance of synaptic and extrasynaptic 5-HT seems to be the principal function of

SERTs, certain cells, notably platelets, use SERTs to acquire 5-HT from the extracellular environment for subsequent release, involving in the processes of platelet activation (Cirillo et al., 1999). Platelets and 5-HT neurons share many common properties, including vesicular monoamine transporters, 5-HT release, biochemistry, identical SERT sequences, and 5-HT receptors (Owens and Nemeroff, 1994). In addition, alterations in platelet SERT have been observed in many psychiatric disorders and vascular diseases in which 5-HT has been implicated (Meltzer et al., 1981). Therefore, platelets have been widely used as a peripheral indicator of central 5-HT metabolism and SERT function (Wirz-Justice, 1988).

Based on a previous study using human embryonic kidney (HEK-293) cells stably transfected with human SERT (hSERT), we reported that activation of PKC and/or inhibi-

ABBREVIATIONS: 5-HT, serotonin; SERT, serotonin transporter; HEK, human embryonic kidney; hSERT, human serotonin transporter; MAPK, mitogen-activated protein kinase; PKC, protein kinase C; ECL, enhanced chemiluminescence; NHS-SS-biotin, sulfosuccinimidyl 2-(biotinamido)ethyl-1,3-dithiopropionate; RIPA, radioimmunoprecipitation assay; PMA, phorbol 12-myristate 13-acetate; PAGE, polyacrylamide gel electrophoresis; MesNa, 2-mercaptoethanesulfonic acid; KT5720, (9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid hexyl ester; DAT, dopamine transporter.

aspet

tion of protein phosphatases decreases 5-HT uptake. This down-regulation of SERT activity is paralleled by a decrease in SERT surface expression, an increase in SERT phosphorylation, and a decrease in SERT-protein phosphatase 2A catalytic subunit association (Ramamoorthy et al., 1998a; Bauman et al., 2000). We also showed that extracellular SERT substrates attenuate PKC-mediated effects on SERT (Ramamoorthy and Blakely, 1999). We demonstrated recently that in HEK-293 cells, PKC activation stimulated SERT internalization and p38 MAPK inhibition attenuated SERT insertion to the plasma membrane (Samuvel et al., 2005). It is interesting that PKC activation resulted in increased SERT basal phosphorylation and p38 MAPK inhibition resulted in reduced SERT basal phosphorylation. These results suggest that whereas PKC is involved in regulated expression of SERT, p38 MAPK may be involved in maintaining normal/basal expression of SERT. It has been shown recently that p38 MAPK activation also induces a trafficking-independent model of SERT stimulation (Zhu et al., 2005). However, many questions still remain unanswered. Is SERT regulation demonstrated in heterologous model systems similar to that of endogenous model systems? Is the PKC-mediated decrease of surface SERT caused by endocytic internalization, decreased exocytic insertion, or both? What are the specific PKC isoform(s) involved in SERT regulation? What residues represent SERT phosphorylation sites, and are they necessary for regulation? In an attempt to define some of the mechanisms by which PKC acutely regulates native SERT, we characterized the time course and pattern of SERT phosphorylation in parallel with SERT functional regulation using rat platelets because they express endogenous SERTs.

In this study, we demonstrate differential time-dependent molecular events associated with PKC-mediated regulation of endogenous SERTs expressed in the platelets. PKC activation in platelets results in reduced SERT function and enhanced SERT basal phosphorylation. It is surprising that PKC activation regulates SERT in a biphasic manner, where the initial phase of inhibition occurs independently of trafficking and the later phase is characterized by an enhanced endocytosis. The biphasic inhibition of SERT is accompanied by a sequential phosphorylation of plasma membrane resident SERT initially on serine residue(s) and then on threonine residue(s). Based on the findings, we conclude that the initial phosphorylation on serine residues might be responsible for changes in the intrinsic properties and/or silencing of SERT and that the phosphorylation on threonine residues later on might trigger internalization of phosphorylated SERT.

Materials and Methods

Materials. Phorbol ester isomers and protease inhibitors were obtained from Sigma-Aldrich (St. Louis, MO). Okadaic acid was purchased from LC Laboratories/Alexis Biochemicals (San Diego, CA). Bisindolylmalemide I was purchased from Calbiochem (San Diego, CA). [^{3}H]5-HT (5-hydroxy-[^{3}H]tryptamine trifluoroacetate), ^{32}PO$_4$ carrier-free orthophosphate, protein A-Sepharose beads, enhanced chemiluminescence (ECL) reagent, and ECL enhanced film were obtained from Amersham Biosciences Inc. (Piscataway, NJ). Horseradish peroxidase-conjugated secondary antibodies were obtained from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA). Monomeric streptavidin beads and EZ-link NHS-sulfo-SS-biotin were purchased from Pierce Chemical (Rockford, IL). All

other reagents were of the highest grade possible from standard commercial sources.

Isolation of Platelets. Rat platelets were collected in a tube containing acid-citrate-dextrose from trunk blood after rapid decapitation. All animal procedures were in accordance with the National Institutes of Health's *Guide for the Care and Use of Laboratory Animals*. Blood was centrifuged immediately at 190g for 15 min at room temperature to obtain platelet-rich plasma. The platelet-rich plasma was centrifuged at 2500g for 15 min at 22°C, and the resulting platelet pellet was gently resuspended in the assay buffer (140 mM NaCl, 5 mM KCl, 10 mM glucose, and 20 mM HEPES, pH 7.2) and used immediately after counting.

Assay of SERT Activity. The activity of SERT in rat platelets was measured by determining the rate of [^{3}H]5-HT accumulation. In brief, 1×10^6 platelets were incubated in assay buffer containing 100 μM pargyline and 100 μM ascorbic acid with or with out the modulators as indicated previously (Samuvel et al., 2005). 5-HT uptake assays in triplicate were initiated by the addition of 10 nM [^{3}H]5-HT for 3 min at 37°C and terminated by the addition of 1 ml of ice-cold assay buffer containing 100 μM imipramine. In some experiments, platelets were washed twice with 10 ml of assay buffer before initiation of 5-HT uptake assay. Assay samples were filtered through GF/F glass filters presoaked in 0.03% polyethylenimine. Radioactivity associated with the filters was counted by liquid scintillation spectrometry. Specific uptake was determined by subtracting the amount of [^{3}H]5-HT accumulated in the presence of 0.01 μM fluoxetine.

Metabolic Labeling and Detection of SERT Phosphorylation by Immunoprecipitations. Platelets ($1–2 \times 10^9$/ml) were incubated with 5 mCi/ml of [^{32}P]orthophosphate for 60 min at 37°C. Stimulation with protein kinase activators was carried out by adding the agents to the same assay mixture and continuing the incubation for appropriate time periods depending on the experiment. At the end of the incubation, the labeled buffer was removed by centrifugation, and platelet pellets were washed with ice-cold buffer and solubilized with RIPA buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, and 1% Na deoxycholate) containing protease and phosphatase inhibitors (1 μM pepstatin A, 250 μM phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 10 mM sodium fluoride, 50 mM sodium pyrophosphate, and 1 μM okadaic acid). The solubilized extracts were centrifuged at 20,000g for 60 min at 4°C. Supernatants were precleared by the addition of 100 μl (3 mg) of protein A-Sepharose beads along with preimmune sera for 1 h at 4°C, and the clear supernatant was subjected to immunoprecipitation. SERT protein was immunoprecipitated overnight at 4°C by the addition of SERT-specific antibody SR-12 (5 μl of SERT antiserum), or preabsorbed SR-12, preimmune sera, and/or protein A Sepharose followed by 1-h incubation with protein A-Sepharose beads (3 mg in 100 μl in RIPA buffer) at 22°C. SR-12 is a rabbit polyclonal antiserum raised against the C-terminal amino acid (596–662) sequence of SERT (Ramamoorthy et al., 1998a; Samuvel et al., 2005). The immunoadsorbents were washed and eluted with the addition of 50 μl of Laemmli sample buffer (62.5 mM Tris-HCl, pH 6.8, 20% glycerol, 2% SDS, 5% β-mercaptoethanol, and 0.05% bromphenol blue). Proteins were separated by 6 to 14% SDS-polyacrylamide gel electrophoresis, and ^{32}P-labeled SERT protein was detected by autoradiography. Quantitation from digitized autoradiograms was evaluated on multiple film exposures to insure quantitation within the linear range of the film. Band density was quantified using NIH Image 1.60.

Phosphoamino Acids Analysis. Phosphoamino acid analysis was performed as described previously (Ramamoorthy and Balasubramanian, 1989). The region of the gel corresponding to ^{32}P-labeled SERT was excised and incubated in 0.5 ml of 0.1 M sodium phosphate buffer, pH 7.0, containing 1% SDS, 3 mM β-mercaptoethanol, and 100 μg of histone (as carrier) with continues overnight shaking at 22°C. The gel was washed once with 0.5 ml of the same buffer without carrier histone. The protein from the combined washings

was precipitated with 20% trichloroacetic acid. The precipitated protein was washed once with 10% trichloroacetic acid, twice with acetone and subjected to acid hydrolysis for 90 min in 5.7 N HCl at 110°C. The HCl was removed by evaporation in vacuo and the samples were subjected to high-voltage electrophoresis on cellulose thin layer plates as described previously (Ramamoorthy and Balasubramanian, 1989). Standard phosphoamino acids were added to the radioactive samples during hydrolysis and located by ninhydrin spray. The [^{32}P]phosphoamino acids from SERT were located by autoradiography and aligned with standards.

Quantification of Surface SERT by Biotinylation. Cell surface biotinylation was performed as described previously (Ramamoorthy et al., 1998b; Jayanthi et al., 2004) with the following modifications. Suspended (1×10^9) platelets were incubated with 0.1 μM β-PMA or vehicle (ethanol) for indicated time periods. Ice-cold assay buffer containing 0.2 mg/ml NHS-SS-biotin was added to the platelet pellet and incubated for 15 min at 4°C. The platelets were washed with ice-cold assay buffer containing 100 mM glycine followed by solubilization with RIPA buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% Na deoxycholate) containing protease and phosphatase inhibitors (1 μM pepstatin A, 250 μM phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 10 mM sodium fluoride, 50 mM sodium pyrophosphate, and 1 μM okadaic acid). The surface-biotinylated proteins were isolated using monomeric avidin beads. SERT levels from total extract, eluted fractions from monomeric avidin beads (surface-biotinylated fraction), and nonbound fractions (intracellular fractions) were analyzed by SDS-PAGE (10%), electroblotted to polyvinylidene difluoride membranes (Amersham), and probed with SERT antibody as described above. Immunoreactive bands were detected by ECL (Amersham Biosciences Inc.). Thereafter, the blots were stripped and probed with anti-calnexin to validate the surface biotinylation, equal protein load and transfer, and platelet integrity. Values of total, nonbiotinylated, and surface SERT protein were normalized using the levels of calnexin in total extract, and values were averaged across three or more experiments. Multiple exposures of immunoblots were obtained to ensure development within the linear range of the film (Kodak X-AR). The band densities were quantified by integrating band density using computer-assisted densitometry (NIH Image 1.60).

To determine the subcellular location of SERT phosphorylation, platelets were metabolically labeled with [^{32}P]orthophosphate (see above for details) followed by biotinylation as described above, except that bound proteins from monomeric avidin beads were eluted using 2 mM free d-biotin. The eluate, unbound fractions, and total extractions were subjected to SERT immunoprecipitations and autoradiography.

Assay of SERT Endocytosis by Reversible Biotinylation. Reversible biotinylation strategy was used as described recently by us (Jayanthi et al., 2004). Isolated platelets (1×10^9) were suspended in 1 ml of ice-cold assay buffer containing 0.1 mg/ml sulfo-NHS-SS-biotin for 20 min at 4°C. After two washes in assay buffer, two tubes were kept at 4°C with the ice-cold assay buffer with or with out β-PMA (to estimate total surface SERT and efficiency of surface biotin removal), and the other tubes were incubated for different times at 37°C in prewarmed assay buffer containing β-PMA (0.1 μM) or vehicle to initiate endocytosis. For each incubation time, samples were kept at 4°C to estimate total surface SERT at a given time period of incubation. Other samples were incubated with 1 ml of ice-cold cleaving solution [50 mM 2-mercaptoethanesulfonic acid (MesNa), 100 mM NaCl, and 50 mM Tris-HCl, pH 8.9] (to estimate internalized SERT) for 20 min and washed three times with assay buffer containing 5 mg/ml iodoacetamide. Because MesNa does not penetrate the plasma membrane, the internalized biotinylated SERT is protected from surface-resident SERT and can be selectively detected. The internalized, biotinylated SERT was quantitated based on the loss of sensitivity to MesNa. Biotinylated SERTs that were resistant to reversal of biotinylation were defined as "the amount of

SERT endocytosed or internalized". All samples were solubilized using RIPA buffer, and biotinylated SERTs were isolated using monomeric avidin beads and then blotted with SERT-specific antibody. To calculate the percentage of SERT internalization, the intensity of the band in the lane where biotinylated platelets stored at 4°C were immediately exposed to MesNa is subtracted as background from all other band densities. In our experimental stripping conditions, the biotinylated SERT present in avidin-bound fractions after MesNa treatment was less than 5% of total biotinylated fraction. The level of SERT in MesNa-resistant fraction was not altered by keeping cell dishes in ice slurry up to 45 min and between the vehicle and β-PMA treatment. In initial experiments, experiments were optimized for dose, time, and pH of the buffer used in stripping procedure with MesNa. We found that MesNa treatment did not completely remove SERT from avidin bound fractions. We always found less than 5% of SERT in avidin-bound fractions after MesNa treatment at 4°C. This residual signal may be arising because of the inability of MesNa to access disulfide bonds for reaction as a result of SERT embedding in the plasma membrane.

To determine ^{32}P-labeled SERT internalization, platelets were metabolically labeled with ^{32}P-orthophosphate (see above for details) followed by reversible biotinylation as described above, except that bound proteins from monomeric avidin beads were eluted using 2 mM d-biotin and subjected to immunoprecipitation of SERT followed by SDS-PAGE and autoradiography.

Statistical Analyses. Values are expressed as mean $\pm$ S.E.M. Analysis by one-way analysis of variance was used followed by post hoc testing (Tukey-Kramer, Bonferroni, and Dunnett's test). Student's t test was performed for paired observations. A value of $p < 0.05$ was considered statistically significant.

Results

PKC Activation Inhibits SERT Activity. Treatment of purified platelets with β-PMA (PKC activator) decreased basal 5-HT uptake. The dose and time dependence of this inhibition is summarized in Fig. 1, A and B, and shows that β-PMA inhibited SERT activity as rapidly as 1 min and over the concentration from 1 to 100 nM. The functional effects of β-PMA were also rapid with 60 to 70% of the maximal inhibition of SERT activity occurring within 5 min. An additional modest decrease in SERT activity was observed after 5 min of incubation with 100 nM β-PMA. Higher concentrations of β-PMA (10–500 nM) showed no further decrease in SERT activity and showed a similar time course as observed with 100 nM β-PMA. Therefore, a 100 nM concentration of β-PMA was chosen for subsequent experiments. α-PMA (100 nM), an inactive analog of β-PMA, did not affect the basal 5-HT uptake (Table 1). It is noteworthy that the inhibitory effect of β-PMA on SERT activity was effectively blocked by the PKC inhibitors staurosporine and bisindolylmaleimide I but not by the PKA inhibitor KT5720 (Table 1). In addition, these inhibitors alone had no effect on 5-HT uptake.

We documented previously that although SERT substrates such as 5-HT attenuate PKC-mediated SERT surface downregulation and SERT phosphorylation, SERT antagonists, such as selective serotonin reuptake inhibitors and cocaine, block the effect of 5-HT (Ramamoorthy and Blakely, 1999). Because platelets store and release 5-HT, a possibility of released 5-HT from platelets during β-PMA treatment could dilute radiolabeled 5-HT, leading to a rapid loss of radiolabeled 5-HT uptake observed at early treatments of β-PMA (Fig. 1A). To determine whether released 5-HT has any effect on PKC-mediated rapid inhibition of 5-HT uptake during early stage, platelets were treated with vehicle or β-PMA in

the presence and absence of cocaine followed by thorough washings before the initiation of 5-HT uptake. Washing vehicle and 100 nM β-PMA-treated (5 min) platelets before 5-HT transport assay exhibited similar effect of β-PMA on


Fig. 1. Effect of β-PMA on 5-HT uptake in isolated rat platelets. A, rat platelets were preincubated with vehicle, 0.5 μM β-PMA for the times indicated; B, treated with indicated concentrations of β-PMA for 45 min; and C, treated with indicated agents followed by washing, before 5-HT uptake assays. 5-HT (10 nM; 3 min) uptake assays were performed as described under *Materials and Methods*. Data are the averaged from three separate experiments and normalized to vehicle (at each time point, open bar), and the mean values $\pm$ S.E.M. are given. Nonspecific uptake was defined as the uptake in the presence of 0.01 μM fluoxetine and subtracted from the total accumulation to yield specific uptake. *, $p <$ 0.05 and **, $p < 0.01$) denote values significantly different from vehicle controls, ANOVA, with Tukey-Kramer post hoc analysis.

5-HT uptake compared with unwashed platelets (Fig. 1C). In addition, incubation of cocaine did not influence 5-HT uptake in the presence and/or absence of β-PMA (Fig. 1C).

Kinetic analysis indicated that β-PMA treatment of platelets affected SERT kinetics differentially based on the time of β-PMA treatment, as shown in Table 2. β-PMA treatment for 5 min significantly decreased apparent substrate affinity for 5-HT (K_m) and V_{max}. However, β-PMA exposure for 30 min decreased V_{max}, but had no significant effect on K_m (Table 2). Similar results were observed when kinetic analysis was performed on data obtained from using washed platelets (data not shown).

PKC Activation Increases SERT Phosphorylation. To determine whether native SERT proteins expressed in platelets are phosphorylated, platelets were metabolically labeled with ^{32}P and immunoprecipitated with SERT-specific antibody (SR-12) and control antisera (Fig. 2A). SDS-PAGE/autoradiography of immunoprecipitates from 0.1 μM β-PMA (30 min)-exposed platelets revealed a broad band centered at ~100 kDa, the size similar from immunoblots for mature SERT proteins in platelets. The ^{32}P-labeled 100 kDa was not immunoprecipitated with preabsorbed SR-12, preimmune sera, and or protein A-Sepharose (Fig. 2A). Our studies rely on the specificity of our immunoprecipitations. Although there is no SERT knockout rat model available to use as a control or no phospho-specific SERT-antibody available for these studies, we find primarily a single band with direct immunoblotting of platelet extracts. A band of similar size was previously reported in rat midbrain synaptosomes (Samuvel et al., 2005) (data not shown). Moreover, immunoprecipitation studies in transfected cells reveal an absence of phosphorylation signal with vector transfections and a band of similar size as seen in platelets when cells are transfected with rat SERT cDNA (data not shown). In addition, immunoblot detections show a band of similar size as seen in platelets when cells are transfected with rat SERT cDNA but not in vector transfections. Thus, this SERT-specific antibody (SR-12) has been tested rigorously with respect to its ability to isolate and detect SERT protein.

We tested whether the time course of β-PMA effect shows any correlation between SERT activity and SERT phosphorylation in platelets. Platelets in the assay buffer without any externally added regulators, showed very low levels SERT phosphorylation (Fig. 2F). Treatment of platelets with 0.1 μM β-PMA increased SERT phosphorylation. The effect of β-PMA was rapid and showed a gradual increase in SERT phosphorylation for up to 10 min, followed by a steep increase at 15 min, and reached a plateau phase thereafter (Fig. 2, F and G). The time course of increased SERT phosphorylation paralleled that of SERT inhibition in early time points (1–10 min) of β-PMA treatment. Major (60–70%) inhibition of SERT activity was achieved within this early time point (1–10 min) after β-PMA treatment and thereafter, only a moderate decrease in SERT activity was observed. The initial gradual increase in SERT phosphorylation corresponded to the sharp decrease in SERT activity achieved within 5 to 10 min, and the later steep increase in SERT phosphorylation, reaching a plateau, corresponded to the later moderate inhibition of 5-HT uptake (Fig. 2, F and G). A similar time-course effect of β-PMA on SERT activity and SERT phosphorylation was observed when higher concentrations of 1 μM β-PMA were used (data not shown). α-PMA (100 nM), an inactive

analog of β-PMA, did not affect SERT phosphorylation (Table 1). The effect of β-PMA was blocked by the PKC inhibitors staurosporine and bis-indolylmaleimide I but not by PKA inhibitor KT5720 (Table 1). Parallel Western blot analysis of SERT and calnexin at each time of β-PMA treatments before immunoprecipitation showed the presence of equal amount of SERT and calnexin proteins in all samples (Fig. 2, B and C). Furthermore, Western blot analysis of SERT from immunodepleted (after removal of protein A-Sepharose-SERT immunocomplex) fractions revealed the absence of SERT protein in the immunodepleted fractions. Western blot analysis of SERT immunocomplexes (immunoprecipitated SERT eluted from protein A-Sepharose) showed the presence of equal SERT band intensity in the immunoprecipitated fractions at all time points of β-PMA treatments (Fig. 2, D and E). These results suggest that the changes in ^{32}P-labeled SERT observed at different times of β-PMA treatment are not caused by uneven use and/or uneven immunoprecipitation of SERT.

PKC Activation Induces Phosphorylation Initially on Serine Residues Corresponding to Early Phase of SERT Inhibition and Then on Threonine Residues Corresponding to Later Phase of SERT Inhibition. Because we observed a biphasic reduction in SERT activity

after β-PMA treatment, we asked whether β-PMA induces phosphorylation of SERT on different amino acid(s) at different time intervals after treatment. ^{32}P-Labeled SERT proteins were immunoisolated from platelets treated with β-PMA either for 5 or 30 min in the presence of phosphatase and protease inhibitors and subjected to gel separation, acid hydrolysis, and phophoamino acid analyses. As shown in Fig. 3, phosphoserine residue(s) but not phosphothreonine or phosphotyrosine residues were detected on phospho-SERT isolated from platelets that were incubated with β-PMA for 5 min. However, both phosphoserine and phosphothreonine residues were detected from platelets that were incubated with β-PMA for 30 min. Densitometry as well as counting of phosphoserine spot showed that there was no increase in the intensity or counts of phosphoserine level between 5 and 30 min of β-PMA treatment (data not shown). Vehicle-treated platelets showed very less SERT phosphorylation and showed no detectable level of phosphoamino acids under 5- or 30-min incubation.

Biphasic Regulation of SERT Function. Unlike in 293-hSERT cells, where PKC activation reduces only SERT V_{max} without affecting the K_m (Qian et al., 1997), in platelets, PKC activation reduced both V_{max} and apparent affinity for 5-HT. This could arise as a result of altered catalytic properties or

TABLE 1
Phosphorylation and regulation of SERT in platelets through PKC-linked pathways

SERT activity and SERT phosphorylation were performed as described under *Materials and Methods*. Platelets were exposed to β-PMA for 5 and 30 min at 37°C. Kinase inhibitors were added to the incubation mixture 15 min before the addition of β-PMA. The concentrations used were 100 nM β-PMA, 100 nM α-PMA, 500 nM staurosporine, 250 nM bisindolylmaleimide I, and 1 μM KT5720. Controls (vehicle) received same concentrations of vehicles. Experiments for SERT activity were conducted in triplicates and the mean values ± S.E.M. from three different experiments were given. For SERT phosphorylation, autoradiograms from three different experiments were scanned, and the mean values ± S.E.M. were given as arbitrary units. Data are expressed as percentage of vehicle. Data were analyzed using one-way factorial ANOVA with post hoc Tukey-Kramer tests.

Treatment	β-PMA Preincubation Time			
	5 min		30 min	
	SERT Activity (% of Control)	SERT Phosphorylation (Band Density, % of Control)	SERT Activity (% of Control)	SERT Phosphorylation (Band Density, % of Control)
		arbitrary units		*arbitrary units*
Vehicle	100.00 ± 5.23	100.00 ± 10.18	100.00 ± 8.92	100.00 ± 9.75
β-PMA	32.24 ± 3.16^a	326.64 ± 33.29^a	28.76 ± 3.34^{a,*}	732.41 ± 29.99^{a,†}
α-PMA	99.26 ± 4.26^a	105.26 ± 5.37^a	100.00 ± 1.53^a	102.29 ± 7.73^a
Stau	105.26 ± 3.12^c	98.84 ± 12.01^c	109.35 ± 2.90^c	108.01 ± 9.26^c
β-PMA + stau	98.87 ± 3.78^b	115.94 ± 17.05^b	100.09 ± 3.12^b	103.97 ± 10.28^b
BIM I	107.57 ± 0.86^c	100.58 ± 9.02^c	104.57 ± 1.11^c	103.59 ± 24.95^c
β-PMA + BIM I	100.13 ± 2.45^b	114.70 ± 12.37^b	97.24 ± 7.51^b	100.78 ± 3.03^b
KT5720	99.56 ± 2.65^c	101.24 ± 3.28^c	100.02 ± 4.56^c	100.76 ± 9.47^c
β-PMA + KT5720	30.35 ± 3.33^a	299.98 ± 11.09^a	26.03 ± 0.84^{a,*}	743.48 ± 14.40^{a,†}

BIM, bisindolylmaleimide I; Stau, staurosporine.
^{a} $P < 0.0001$ significantly different from vehicle.
^{b} $P < 0.001$ significantly different from β-PMA.
^{c} Not significantly different from vehicle.
* Not significantly different from β-PMA-induced SERT activity inhibition at 5-min preincubation time.
† $P < 0.001$ significantly different from β-PMA-induced SERT phosphorylation at 5-min preincubation time.

TABLE 2
Time-course effect of β-PMA on V_{max} and K_m values of 5-HT uptake

Platelets were exposed to 0.1 μM β-PMA for 5 and 30 min at 37°C. Controls (vehicle) received same concentrations of vehicles. Experiments for SERT activity were conducted in triplicates as described under *Materials and Methods*, and the mean values ± S.E.M. from three different experiments are given. Nonlinear curve fits of data for uptake used the generalized Michaelis-Menten equation to obtain V_{max} and K_m values for 5-HT uptake. Data were analyzed using one-way ANOVA with post hoc Tukey-Kramer tests.

β-PMA Treatment	K_m		V_{max}	
	Vehicle	β-PMA	Vehicle	β-PMA
	nM		*pmol/10^6 platelets/min*	
5 min	54.33 ± 2.18	164.22 ± 1.96*	116.43 ± 2.45	58.43 ± 1.20*
30 min	56.12 ± 1.25	64.76 ± 1.27$^#$	123.10 ± 0.98	46.32 ± 3.36*

* $p < 0.05$ versus vehicle.
$^#$ $p < 0.05$ versus β-PMA, 5 min.

functional silencing of plasma membrane resident SERT and/or altered surface SERT density. The initial increase in SERT phosphorylation (phosphorylation on serine residues) was correlated with a dramatic decrease in SERT activity

Fig. 2. Effect of β-PMA on SERT phosphorylation and 5-HT uptake. A, rat platelets ($1–2 \times 10^9$/ml) were metabolically labeled with [^{32}P]orthophosphate for 60 min at 37°C and treated with 0.1 μM β-PMA for 30 min. RIPA extraction, immunoprecipitation, SDS-PAGE, and autoradiography were performed as described under *Materials and Methods*. The ^{32}P-labeled SERT ($\sim$100 kDa) is specifically immunoprecipitated with SERT-immune sera SR-12. Parallel experiments were performed using preimmune sera, preabsorbed SR-12, and protein A beads so as to validate specificity of SERT specific antibody SR-12. Note that no ^{32}P-labeled SERT band is observed when preimmune serum or protein A-Sepharose or preabsorbed SR-12 antibody was used. B to E, rat platelets ($1–2 \times 10^9$/ml) were metabolically labeled with [^{32}P]orthophosphate for 60 min at 37°C and treated with 0.1 μM β-PMA and vehicle for indicated times. RIPA extraction, Western blot analysis, immunoprecipitation, SDS-PAGE, and autoradiography were performed as described under *Materials and Methods*. SERT (B) and calnexin (C) Western blots from total extract before subjected to SERT immunoprecipitation (ip), D, SERT Western blot from samples after SERT immunoprecipitation. E, SERT Western blot from SERT immunoprecipitation complex. F, an autoradiogram of ^{32}P-labeled SERT. G, relative intensity of ^{32}P-labeled SERT and 5-HT uptake as in Fig. 1A. Each blot is a representative of four separate experiments. Data are presented as mean values $\pm$ S.E.M. $*$ and #, $p < 0.05$ and $**$ and ##, $p < 0.01$ indicate significant differences compared with 0-min-treated controls, ANOVA with Bonferroni post hoc analysis.

after the 5-min treatment with β-PMA. There was only a little reduction in SERT activity thereafter, although SERT phosphorylation (phosphorylation on threonine residues) kept increasing during this time (Fig. 2, F and G). These results suggest that the phosphorylation of serine residue(s) influences SERT activity by mechanisms that are different from those mediated by threonine phosphorylation. To examine the mechanisms underlying this biphasic regulation of SERT activity, surface biotinylation experiments were performed to quantitate SERT levels at the cell surface and in the cell interior, both in control and β-PMA-treated platelets after 5- and 30-min incubations. SR-12 SERT antibody detects essentially equally both biotinylated and nonbiotinylated SERT in platelets (data not shown). Figure 4, A and B, shows the density of SERT immunoreactivity from biotinylated and nonbiotinylated fractions from platelets treated with 100 nM β-PMA or vehicle. The amount of SERT immunoreactivity from the total extract did not change after 5- or 30-min treatment with β-PMA. Although, a decrease in SERT activity (Figs. 1A and 2G) was evident after 5-min β-PMA treatment, there was no change either in the cell surface SERT (biotinylated fraction) or in the intracellular SERT (nonbiotinylated) compared with control vehicle treatment. However, a decrease in cell surface SERT ($\sim$80% of control) and a simultaneous increase in intracellular SERT immunoreactivity was evident in platelets after 30-min β-PMA treatment (Fig. 4, A and B). Subsequent stripping and reprobing with calnexin, an intracellular marker, revealed less than 2% of total calnexin in biotinylated fractions (Fig. 4A).

Enhanced SERT Endocytosis Accounts for Decreased Surface SERT Density and Later Phase of SERT Inhibition. Changes in the rate of endocytosis can alter surface expression and hence functional properties of a protein. To determine whether the β-PMA induced decrease in surface SERT occurring in the later phase was caused by increased SERT endocytotic internalization, a reversible biotinylation strategy was exploited. The amount of biotinyl-


Fig. 3. Effect of β-PMA on phosphoamino acid composition of SERT. ^{32}P-Labeled platelets as in Fig. 2 were treated with 0.1 μM β-PMA and vehicle for 5 and 30 min. The region corresponding to ^{32}P-labeled SERT bands were excised from gel, eluted, acid hydrolyzed, and subjected to high-voltage electrophoresis. Details are given in *Materials and Methods*. A representative autoradiogram showing the presence of [^{32}P]phosphoserine and [^{32}P]phosphothreonine is presented. Locations of ninhydrin-stained standard phosphoamino acids (PS, phosphoserine; PT, phosphothreonine; PY, phosphotyrosine) are indicated. Because of low levels of ^{32}P-labeled SERT in vehicle-treated samples, there were no detectable ^{32}P-labeled phosphoamino acids.

ated SERT protein was determined for the surface (platelets left at 4°C without cleavage of surface biotin, total biotinylated SERT) and intracellular (after MesNa treatment, internalized biotinylated SERT) pools (Fig. 5). Biotinylation of platelets using NHS-SS-Biotin before β-PMA exposure did not affect SERT activity or β-PMA-mediated SERT inhibition or SERT immunoreactivity (data not shown). Control experiments performed at 4°C, where endocytosis was arrested, revealed a background signal of approximately 4 to 8% compared with platelets incubated at 37°C (Fig. 5A). This probably represents biotinylated surface proteins that were not completely cleaved by MesNa. This background signal did not seem to be consistently altered by β-PMA treatment. After 5-min treatment with β-PMA, there was no significant change in the level of biotinylated SERT in MesNa protected fractions compared with vehicle-treated control (Fig. 5, A and B). However, a significant increase in the amount of biotinylated SERT in MesNa-resistant fractions was observed from

platelets treated with β-PMA for 30 min at 37°C compared with respective vehicle-treated control (Fig. 5, A and B). The percentage of internalization shown in Fig. 5B is consistent with a decrease in surface SERT that occurred only at the later phase of SERT inhibition (Fig. 4, A and B).

PKC-Mediated SERT Phosphorylation Occurs at the Plasma Membrane. Based on the above-mentioned results, we predict that the early (5-min) serine phosphorylation of SERT might be occurring at the cell surface, and subsequent threonine phosphorylation may provide a signal for SERT endocytotic internalization and/or occur in parallel with SERT internalization. To test this hypothesis, using metabolically ^{32}P-labeled platelets, we specifically isolated surface-biotinylated, ^{32}P-labeled SERT from intracellular SERT after β-PMA treatment by sequential SERT isolation using streptavidin-agarose beads and SR-12 SERT antibody. We found ^{32}P-labeled SERT in the plasma membrane (biotinylated) fraction with no detectable ^{32}P-labeled SERT in the intracellular pool (nonbiotinylated fraction) after 5-min treatment with β-PMA (Fig. 6, A and B). In contrast, after 30 min of β-PMA exposure, little or no ^{32}P-labeled SERT was detected in the plasma membrane fraction with a parallel increase in the ^{32}P-labeled SERT in the intracellular pool (Fig. 6, A and B). The amount of SERT phosphorylation


Fig. 4. Effect of β-PMA on surface expression of SERT. Rat platelets were treated with 0.1 μM β-PMA and vehicle for 5 and 30 min. Surface proteins were biotinylated and recovered from solubilized extracts by monomeric avidin-beads, and SERT was detected by immunoblot as described under *Materials and Methods*. A, representative SERT immunoblot of four separate experiments is shown. B, quantitative analysis of SERT band densities. SERT proteins were quantified using NIH Image, and the densities of SERT band from three separate experiments are presented as mean ± S.E.M. ∗, p < 0.05 indicates significant changes in cell surface and intracellular SERT after β-PMA compared with vehicle treatment for 30 min. #, p < 0.05 denotes significant changes compared with β-PMA and vehicle treatment for 5 min, ANOVA followed by Bonferroni method.


Fig. 5. Effect of β-PMA on SERT endocytosis. A, platelets were surface-biotinylated using cleavable biotin (sulfo-NHS-SS-biotin), incubated for 5 and 30 min at 37°C in the presence or absence 0.1 μM β-PMA for endocytosis, and the remaining surface-accessible biotin was cleaved and removed with MesNa treatment (see *Materials and Methods* for details). The internalized biotin-bearing proteins were recovered by avidin agarose isolation, and SERT protein was quantified by immunoblot. Some surface-biotinylated platelets were kept at 4°C throughout the procedure and biotinylated SERT were analyzed before (signal represents total SERT biotinylated on the surface) and after treatment (signal represents the effectiveness of MesNa cleaving surface biotin-SS-linked proteins) with MesNa. B, quantation of biotinylated SERT bands. Biotinylated SERT was quantified, and the percentages internalized (compared with total surface SERT) in three separate experiments are shown as the mean ± S.E.M. Values from β-PMA treatments were compared with vehicle treatments using Student's *t* test; ∗, p < 0.05.

observed in the total extract at 30 min was approximately equal to the sum of the SERT phosphorylation observed at the cell surface and in the intracellular pool (data not shown). To test whether phosphorylated SERT from the plasma membrane indeed is internalized, ^{32}P-labeled SERT was isolated from MesNa-resistant fractions as described previously (see *Materials and Methods*) using reversible biotinylation method followed by sequential isolation using streptavidin-agarose beads and SR-12 SERT antibody (Fig. 6, C and D). MesNa treatment in control experiments performed at 4°C where endocytosis was arrested revealed a background signal of approximately 5 to 10% of that from platelets incubated at 37°C or from total amount of ^{32}P-labeled SERT (Fig. 6C). This probably represents biotinylated surface proteins that were not completely cleaved by MesNa. This background signal was unaltered by β-PMA (5- or 30-min) treatment. Although, a severalfold increase in total ^{32}P-labeled SERT was observed after 5-min β-PMA treatment, no significant increase in ^{32}P-labeled SERT was detected from MesNa-resistant fractions compared with the background signal (Fig. 6, C and D). Almost 70 to 80% of ^{32}P-labeled SERT was detected in MesNa-resistant fraction after treatment with

β-PMA for 30 min at 37°C compared with total ^{32}P-labeled SERT (Fig. 6, C and D).

Discussion

The elucidation of the mechanisms underlying SERT regulation and signal transduction pathways are crucial to the understanding of SERT function in 5-HT homeostasis. PKC is a well established regulator for SERT activity (Anderson and Horne, 1992; Qian et al., 1997; Ramamoorthy et al., 1998a). Early studies using heterologously expressed hSERT in HEK-293 cells showed that β-PMA increased SERT phosphorylation with parallel decreases in the V_{max} for uptake of 5-HT and surface SERT density (Qian et al., 1997; Ramamoorthy et al., 1998a). Triggering SERT activity by providing SERT substrates and co-ions attenuated this PKC-mediated decrease in SERT phosphorylation and SERT surface density (Ramamoorthy and Blakely, 1999). 5-HT suppresses SERT phosphorylation, suggesting the surface pool is phosphorylated, but this has not been confirmed directly. The results of the present study demonstrate that, similar to heterologously expressed SERT, native SERT expressed in


Fig. 6. Subcellular location of phosphorylation of SERT: A, SERT phosphorylation on the surface: rat platelets were labeled with [^{32}P]orthophosphate and treated with 0.1 μM β-PMA or vehicle for 5 and 30 min followed by surface biotinylation as in Fig. 4. Solubilized proteins were subjected to two successive isolations. Biotin-linked proteins were separated from non–biotin-linked proteins by monomeric avidin beads and bound proteins were eluted using 2 mM d-biotin. ^{32}P-labeled SERT proteins from eluate, unbound fractions, total extracts were immunoprecipitated using SERT specific SR-12 antibody and subjected to SDS-PAGE and autoradiography. B, quantitation of ^{32}P-labeled SERT. Data are presented as mean values ± S.E.M. ∗, $p < 0.05$ and ∗∗, $p < 0.01$ indicate significant differences compared with vehicle controls (ANOVA followed by Bonferroni method). C, internalization of ^{32}P-labeled SERT. [^{32}P]orthophosphate-labeled platelets were surface biotinylated using cleavable biotinylating agent Sulfo-NHS-SS-biotin at 4°C. Platelets were then treated with 0.1 μM β-PMA or vehicle for 5 and 30 min followed by biotin stripping as in Fig. 5. Two successive isolations of ^{32}P-labeled SERT from the avidin bead eluates and SERT immunoprecipitations and autoradiography are as described in A. D, quantitation of internalized ^{32}P-labeled SERT. ∗∗∗, $p < 0.001$ indicates significant change in the level of MesNa-resistant ^{32}P-labeled SERT compared with 5-min β-PMA treatment. Experiment was repeated three times with essentially equivalent results.

platelets is inhibited by PKC activation, and this inhibition is accompanied by a decrease in surface expression of SERT protein. However, analysis of 5-HT transport kinetics indicated a significant decrease in both the transport capacity (V_{max}) and the apparent affinity for 5-HT after 5-min β-PMA treatment. It is interesting that 30 min of β-PMA treatment caused a reduction only in V_{max}. The change in the apparent substrate affinity suggests that PKC activation results in altered intrinsic transport properties. Future studies examining endocytotic-signal and/or PKC-phosphorylation defective SERTs should reveal the difference between intrinsic and trafficking mediated SERT regulation.

Surface biotinylation studies indicated no change in cell surface SERT level after 5-min exposure to β-PMA but a significant decrease in cell surface SERT level after a 30-min incubation. These results further support the idea that early inhibition of SERT is caused by altered intrinsic transport properties and/or silencing of 5-HT transport rather than by trafficking changes. The later inhibition was caused by a redistribution of SERT protein from the plasma membrane to cytosolic fraction via increased SERT endocytosis. Although we observed a rapid ~90% inhibition of 5-HT uptake after β-PMA treatment, kinetic analysis showed a 50 to 60% reduction in V_{max} values. It is probable that β-PMA treatment could cause release of 5-HT from platelets and influence the effect of β-PMA on SERT regulation. Previous studies have shown that SERT substrates such as 5-HT attenuate PKC effects on SERT regulation and that the effect of 5-HT is blocked by SERT antagonists such as cocaine (Ramamoorthy and Blakely, 1999; Whitworth et al., 2002). Thus, the observed rapid decrease in 5-HT uptake, changes in 5-HT uptake kinetics, SERT surface expression, and SERT phosphorylation within the early β-PMA treatment could represent a composite of influence of released 5-HT on PKC-mediated SERT effect from platelets. However, in our current study with washed platelets and/or β-PMA treatment in the presence of SERT blocker, cocaine does not significantly affect the β-PMA effect on 5-HT uptake (Fig. 1C). If the rapid, early inhibition of 5-HT by β-PMA were the result of enhancement of release of 5-HT from platelets by β-PMA influencing PKC-mediated regulation of 5-HT uptake, there would have been a lesser inhibition in washed platelets and that cocaine should prevent this effect. Although the possibility that the influence of released 5-HT from platelets on SERT as well as 5-HT receptors could not be completely ruled out in the current study, the data support the assertion that the early rapid inhibition of 5-HT uptake caused by β-PMA treatment may not be associated with release of 5-HT from platelets.

It is interesting that the early inhibition was accompanied by an increase in SERT phosphorylation on serine residues with the later inhibition being associated with an increase in SERT phosphorylation on threonine residues. Phosphorylation of serine and threonine residues has been described for DAT expressed in rat brain synaptosomes and cells transfected with DAT after PKC activation (Foster et al., 2002; Granas et al., 2003; Lin et al., 2003). Although it is not known whether direct SERT phosphorylation modulates SERT activity, trafficking, or both, the current data suggest that the dual-stage SERT phosphorylation may have functional importance in SERT regulation. Changes in transport kinetics (both transport capacity and substrate apparent affinity) and the dual-stage phosphorylation of SERT suggest that the

early phosphorylation on serine residues might be involved in changing the intrinsic transport properties having a major role in SERT inhibition. The later phosphorylation on threonine residues might be involved in SERT internalization with less direct effect on transport function. Examination of the time course of internalization of phosphorylated SERT indicated that up to 5 min, phosphorylated SERTs are present only at the plasma membrane level, and internalized phospho-SERT could be isolated after 5 min. It is therefore possible that early SERT phosphorylation on serine residues may not only perturb SERT function (render SERT nonfunctional) but also bring about conformational changes exposing threonine residues on SERT proteins for later phosphorylation by PKC or another kinase downstream of PKC. Thus, phosphorylation on threonine residues may provide a signal for SERT internalization.

Activation of PKC generally leads to inhibition of transporter-mediated uptake and sequestration of transporter protein from the cell surface to intracellular compartment (Beckman and Quick, 1998; Zahniser and Doolen, 2001; Ramamoorthy, 2002; Robinson, 2003). However, recently, Lin et al. (2003) showed a change in DAT cell surface expression after phosphoinositide 3-kinase and mitogen-activated protein kinase kinase 1/2 kinase modulation but not by PKC activation, even though there was an ~30% inhibition of DA uptake. This suggests that changes in transporter activity cannot always be accounted for by changes in surface transporter level (Lin et al., 2003). PKC activation also results in transporter phosphorylation, suggesting an association between transporter phosphorylation and internalization (Ramamoorthy et al., 1998a; Foster et al., 2003; Lin et al., 2003; Vaughan, 2004). It has been shown recently that DAT exhibits normal PKC-mediated transporter kinetics and trafficking patterns even when PKC-mediated DAT phosphorylation is eliminated by mutation of predicted intracellular PKC sites on DAT (Granas et al., 2003), suggesting that PKC-mediated DAT phosphorylation and down-regulation are two independent phenomena. It is possible that PKC-mediated SERT phosphorylation and down-regulation may be independent events occurring in parallel. Although it is not known whether direct SERT phosphorylation is essential for transporter down-regulation, it is possible that transporter phosphorylation may have distinct roles in different transporters. Indeed, the N and C termini that contain the majority of consensus phosphorylation sites are poorly conserved among the members of monoamine transporter family (Vaughan, 2004). SERT and DAT also differ in the effect of substrate and inhibitors on their PKC-mediated down-regulation (Daniels and Amara, 1999; Ramamoorthy and Blakely, 1999; Saunders et al., 2000; Chi and Reith, 2003). Experiments with molecular mutant(s) of SERT phosphate acceptor sites are currently underway to establish any direct link between PKC-linked SERT phosphorylation and inhibition of 5-HT transport.

One quantitative aspect of the data in the present study is noteworthy. More than two-thirds (majority) of the inhibition of SERT activity was achieved within 5 min of β-PMA treatment (Fig. 1), a time when no detectable decreases in surface SERT protein were evident (Fig. 4). After 30 min, when PKC activation decreased SERT surface expression (Fig. 4), a modest additional decrease in SERT activity occurred (Figs. 1 and 2). Although the activity and surface density data were

not obtained in the same platelets, it is evident that the decrease in SERT activity at 5 min is caused by decreased intrinsic SERT transport activity. There is convincing evidence that transporter proteins exist in association with partner proteins such as protein phosphatase 2A catalytic subunit, PICK1, Hic-5, syntaxin 1A (Bauman et al., 2000; Torres et al., 2001; Carneiro et al., 2002; Quick, 2003; Sung et al., 2003). There is no current evidence that binding of these partner (transporter-associated) proteins to transporter per se alters transporter phosphorylation. However, it is possible that association of these proteins with the transporter can be a mechanism of altering transporter activity without changing transporter abundance in the plasma membrane. As indicated above, this may be mediated by SERT phosphorylation on serine residues, binding to associated proteins, or both. It has recently been demonstrated that activation of p38 MAPK-linked pathways in multiple models, including platelets, increases 5-HT transport activity without enhancing SERT trafficking, an effect linked to an increase in 5-HT binding affinity (Zhu et al., 2005). Our studies with PKC activation may represent antagonism of this same process or may involve population of a novel inactive state. Our studies also indicate the existence of a correlation between SERT activity, SERT phosphorylation and SERT internalization. However, the stoichiometry of SERT phosphorylation and the mechanisms underlying this relationship remain to be elucidated.

In summary, the data from the present study suggest a model of biphasic regulation of SERT activity by PKC activation involving dual mechanisms. Immediate inhibition is mediated by changes in intrinsic activity of SERT and/or silencing SERT function and is associated with serine phosphorylation. A more sustained inhibition is produced by enhanced endocytic removal of SERT from the plasma membrane. At present, the fates of the remaining surface transporters and the transporters that have undergone endocytosis are unknown. We speculate two possible ways of biphasic SERT regulation that are consistent with the empirical observations. One possibility is that serine residues on certain fractions of SERT undergo phosphorylation resulting in dramatic reductions in transport via yet unidentified mechanisms at 5 min. At 30 min, the serine-phosphorylated SERT fraction undergoes further phosphorylation on threonine residues triggering SERT endocytosis. Internalized SERT may be dephosphorylated by an associated phosphatase-triggering exocytotic insertion into the plasma membrane. The rate of exocytotic insertion of SERT (now dephosphorylated and reactivated) might balance the rate of endocytosis of SERT, resulting in very little additional decrease in SERT function. The second possibility is that serine residues on all of SERT undergo phosphorylation, resulting in dramatic reduction in transport. A restricted population of serine-phosphorylated SERT then undergoes phosphorylation on threonine residues, triggering internalization. The remainder of serine phosphorylated SERT might recover its function via reversal of phosphorylation, binding to associated proteins, or both. In both ways, total cellular SERT phosphorylation remains elevated at 30 min due mainly to the intracellular endocytosed pool of SERT.

Platelets express 5-HT1A receptors and thus precludes an examination of the influence of SERT-mediated 5-HT effect on PKC-mediated SERT sequential phosphorylation and trafficking. Further studies are needed to understand the time-dependent differential influence of β-PMA on this complex SERT regulation in the presence of SERT substrates via SERT and 5-HT receptors. The active transport of 5-HT by platelet SERT is thought to be important in maintaining the circulating concentration of 5-HT below the levels required to activate vascular smooth cells and platelet 5-HT receptors (Stoltz, 1985; Nemeroff et al., 1998; Musselman et al., 2002). Therefore, the above-mentioned findings suggest that SERT function in platelets may be regulated by kinases and phosphatases linked to endogenous receptors and that this regulation may play a role in maintaining blood 5-HT levels. Any perturbations in this homeostatic regulation may contribute to elevated platelet 5-HT levels reported in some autistic subjects (Anderson et al., 1990; Cook and Leventhal, 1996; Cook et al., 1997).

References

Anderson GM and Horne WC (1992) Activators of protein kinase C decrease serotonin transport in human platelets. *Biochim Biophys Acta* **1137:**331–337.

Anderson GM, Horne WC, Chatterjee D, and Cohen DJ (1990) The hyperserotonemia of autism. *Ann NY Acad Sci* **600:**331–343.

Barker EL and Blakely RD (1995) Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs, in *Psychopharmacology: The Fourth Generation of Progress* (Bloom FE and Kupfer DJ eds) pp 321–333, Raven Press, New York.

Bauman AL, Apparsundaram S, Ramamoorthy S, Wadzinski BE, Vaughan RA, and Blakely RD (2000) Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. *J Neurosci* **20:**7571–7578.

Beckman ML and Quick MW (1998) Neurotransmitter transporters: regulators of function and functional regulation. *J Membr Biol* **164:**1–10.

Carneiro AM, Ingram SL, Beaulieu JM, Sweeney A, Amara SG, Thomas SM, Caron MG, and Torres GE (2002) The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter. *J Neurosci* **22:**7045–7054.

Chi L and Reith ME (2003) Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. *J Pharmacol Exp Ther* **307:**729–736.

Cirillo P, Golino P, Ragni M, Battaglia C, Pacifico F, Formisano S, Buono C, Condorelli M, and Chiariello M (1999) Activated platelets and leucocytes cooperatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors. *Cardiovasc Res* **43:**210–218.

Cook EH Jr, Courchesne R, Lord C, Cox NJ, Yan S, Lincoln A, Haas R, Courchesne E, and Leventhal BL (1997) Evidence of linkage between the serotonin transporter and autistic disorder. *Mol Psychiatry* **2:**247–250.

Cook EH Jr and Leventhal BL (1996) The serotonin system in autism. *Curr Opin Pediatr* **8:**348–354.

Daniels GM and Amara SG (1999) Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. *J Biol Chem* **274:**35794–35801.

Foster JD, Pananusorn B, Cervinski MA, Holden HE, and Vaughan RA (2003) Dopamine transporters are dephosphorylated in striatal homogenates and in vitro by protein phosphatase 1. *Brain Res Mol Brain Res* **110:**100–108.

Foster JD, Pananusorn B, and Vaughan RA (2002) Dopamine transporters are phosphorylated on N-terminal serines in rat striatum. *J Biol Chem* **277:**25178–25186.

Granas C, Ferrer J, Loland CJ, Javitch JA, and Gether U (2003) N-Terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization. *J Biol Chem* **278:**4990–5000.

Jacobs BL and Fornal CA (1995) Serotonin and behavior: a general hypothesis, in *Psychopharmacology: The Fourth Generation of Progress* (Bloom FE and Kupfer DJ eds) pp 461–469, Raven Press, New York.

Jayanthi LD, Samuvel DJ, and Ramamoorthy S (2004) Regulated internalization and phosphorylation of the native norepinephrine transporter in response to phorbol esters: evidence for localization in lipid rafts and lipid raft-mediated internalization. *J Biol Chem* **279:**19315–19326.

Lin Z, Zhang PW, Zhu X, Melgari JM, Huff R, Spieldoch RL, and Uhl GR (2003) Phosphatidylinositol 3-kinase, protein kinase C and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. *J Biol Chem* **278:**20162–20170.

Meltzer HY, Arora RC, Baber R, and Tricou BJ (1981) Serotonin uptake in blood platelets of psychiatric patients. *Arch Gen Psychiatry* **38:**1322–1326.

Murphy DL, Lerner A, Rudnick G, and Lesch KP (2004) Serotonin transporter: gene, genetic disorders and pharmacogenetics. *Mol Interv* **4:**109–123.

Musselman DL, Marzec U, Davidoff M, Manatunga AK, Gao F, Reemsnyder A, Duggirala S, Larsen H, Taylor RW, Hanson S, et al. (2002) Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment. *Depress Anxiety* **15:**91–101.

Nemeroff CB, Musselman DL, and Evans DL (1998) Depression and cardiac disease. *Depress Anxiety* **1:**71–79.

Owens MJ and Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. *Clin Chem* **40:**288–295.

Qian Y, Galli A, Ramamoorthy S, Risso S, DeFelice LJ, and Blakely RD (1997) Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. *J Neurosci* **17:**45–47.

Quick MW (2003) Regulating the conducting states of a mammalian serotonin transporter. *Neuron* **40:**537–549.

Ramamoorthy S (2002) Regulation of monoamine transporters: regulated phosphorylation, dephosphorylation and Trafficking, in *Neurotransmitter Transporter: Structure, Function and Regulation* (Reith MEA ed) pp 1–23, Humana Press, Totowa, NJ.

Ramamoorthy S and Balasubramanian AS (1989) Stimulation by ATP-Mg^{2+} and inactivation by cyclic-AMP-dependent phosphorylation of a cytosolic monkey brain aminopeptidase. *Biochem J* **258:**777–783.

Ramamoorthy S and Blakely RD (1999) Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. *Science (Wash DC)* **285:**763–766.

Ramamoorthy S, Giovanetti E, Qian Y, and Blakely RD (1998a) Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. *J Biol Chem* **273:**2458–2466.

Ramamoorthy S, Melikian HE, Qian Y, and Blakely RD (1998b) Biosynthesis, N-glycosylation and surface trafficking of biogenic amine transporter proteins. *Methods Enzymol* **296:**347–370.

Robinson MB (2003) Signaling pathways take aim at neurotransmitter transporters. *Sci STKE* **2003:**50.

Samuvel DJ, Jayanthi LD, Bhat NR, and Ramamoorthy S (2005) A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. *J Neurosci* **25:**29–41.

Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, and Galli A (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. *Proc Natl Acad Sci USA* **97:**6850–6855.

Stoltz JF (1985) Uptake and storage of serotonin by platelets, in *Serotonin and the Cardiovascular System* (Vanhoutte PM ed) pp 37–42, Raven Press, New York.

Sung U, Apparsundaram S, Galli A, Kahlig KM, Savchenko V, Schroeter S, Quick MW, and Blakely RD (2003) A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. *J Neurosci* **23:**1697–1709.

Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI, Staudinger J, and Caron MG (2001) Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. *Neuron* **30:**121–134.

Vaughan RA (2004) Phosphorylation and regulation of psychostimulant-sensitive neurotransmitter transporters. *J Pharmacol Exp Ther* **310:**1–7.

Whitworth TL, Herndon LC, and Quick MW (2002) Psychostimulants differentially regulate serotonin transporter expression in thalamocortical neurons. *J Neurosci* **22:**RC192.

Wirz-Justice A (1988) Platelet research in psychiatry. *Experientia* **44:**145–152.

Zahniser NR and Doolen S (2001) Chronic and acute regulation of Na$^+$/Cl$^-$-dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors and signaling systems. *Pharmacol Ther* **92:**21–55.

Zhu C-B, Carneirom AM, Dostmann WR, Hewlett W, and Blakely RD (2005) p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, PP2A-dependent process. *J Biol Chem*, in press.

Address correspondence to: Dr. Sammanda Ramamoorthy, Department of Physiology and Neuroscience, Medical University of South Carolina, 173 Ashley Ave., BSB 403, Charleston, SC 29425. E-mail: rama@musc.edu

MOL PHARM

MOLECULAR PHARMACOLOGY

aspet